Stock Research for CRME

CRME
Current Price

$1.4700


Latest Update: 2018-02-16 15:59:00

High
$ 1.4700
Low
$ 1.4700
Close
$ 1.4700
Volume
100
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

CRME Stock Chart & Research Data

The CRME chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CRME chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CRME Due diligence Resources & Stock Charts

The CRME stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CRME Detailed Price Forecast - CNN Money CNN View CRME Detailed Summary - Google Finance
Yahoo View CRME Detailed Summary - Yahoo! Finance Zacks View CRME Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CRME Trends & Analysis - Trade-Ideas Barrons View CRME Major Holders - Barrons
NASDAQ View CRME Call Transcripts - NASDAQ Seeking View CRME Breaking News & Analysis - Seeking Alpha
Spotlight View CRME Annual Report - CompanySpotlight.com OTC Report View CRME OTC Short Report - OTCShortReport.com
TradeKing View CRME Fundamentals - TradeKing Charts View CRME SEC Filings - Bar Chart
WSJ View Historical Prices for CRME - The WSJ Morningstar View Performance/Total Return for CRME - Morningstar
MarketWatch View the Analyst Estimates for CRME - MarketWatch CNBC View the Earnings History for CRME - CNBC
StockMarketWatch View the CRME Earnings - StockMarketWatch MacroAxis View CRME Buy or Sell Recommendations - MacroAxis
Bullish View the CRME Bullish Patterns - American Bulls Short Pains View CRME Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CRME Stock Mentions - StockTwits PennyStocks View CRME Stock Mentions - PennyStockTweets
Twitter View CRME Stock Mentions - Twitter Invest Hub View CRME Investment Forum News - Investor Hub
Yahoo View CRME Stock Mentions - Yahoo! Message Board Seeking Alpha View CRME Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for CRME - SECform4.com Insider Cow View Insider Transactions for CRME - Insider Cow
CNBC View CRME Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CRME - OTC Markets
Yahoo View Insider Transactions for CRME - Yahoo! Finance NASDAQ View Institutional Holdings for CRME - NASDAQ


Stock Charts

FinViz View CRME Stock Insight & Charts - FinViz.com StockCharts View CRME Investment Charts - StockCharts.com
BarChart View CRME Stock Overview & Charts - BarChart Trading View View CRME User Generated Charts - Trading View


Latest Financial News for CRME

Best TSX Growth Stocks
Posted on Thursday February 15, 2018

Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...


Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Posted on Thursday February 08, 2018

NASDAQ:CRME  TSX:COM VANCOUVER , Feb. 8, 2018 /PRNewswire/ -   Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...


CRME: Initiating Coverage
Posted on Monday February 05, 2018

Through its acquisition of Correvio in late 2013, Cardiome procured a salesforce, EU licenses and worldwide sales rights (ex-US) for Aggrastat.  This action provided immediate sales and infrastructure to commercialize the internally developed Brinavess as well as the structure necessary to layer on additional products.  Following this initial transaction, Cardiome has obtained the rights to four other products, including two complementary anti-infectives. Based on our forecasts which include revenues for currently licensed drugs and a probability-weighted contribution from Trevyent, we expect breakeven on an operational basis in 2020.  This forecast assumes growth in all products, with a greater contribution from Xydalba and Zevtera in 2018 and initial contribution from Trevyent in 2020.


Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen
Posted on Tuesday January 23, 2018

Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen


What Is The Future Prospect For Healthcare And Cardiome Pharma Corp (TSE:COM)?
Simply Wall St - 16 hours ago
Cardiome Pharma Corp (TSX:COM), a CA$62.69M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and ...
Cardiome Pharma Corp. (COM) EPS Estimated At $-0.24 - BZ Weekly

Cardiome Pharma Corp.
MarketWatch - Dec 22, 2015
Cardiome Pharma Corp. Cardiome Pharma Corp. is a pharmaceutical company, which engages in the provision of development and commercialization of medical products.

News Cardiome Pharma Corp.CRME
Wall Street Journal - Feb 12, 2011
P/E Ratio (TTM): The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period ...

Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio ...
Canada NewsWire (press release) - Sep 12, 2017
VANCOUVER, Sept. 12, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera®/Mabelio®. Under the terms of the agreement, Basilea ...
Swiss stocks - Factors to watch on Sept 12 - Reuters

Enter a stock symbol to view the stock details.